

Contents

Preface *XIII*

List of Contributors *XV*

1	Introduction: Antibody Structure and Function	1
	<i>Arvind Rajpal, Pavel Strop, Yik Andy Yeung, and Javier Chaparro-Riggers, and Jaume Pons</i>	
1.1	Introduction to Antibodies	1
1.2	General Domain and Structure of IgG	6
1.2.1	Structural Aspects Important for Fc Fusion(s)	6
1.2.1.1	Fc Protein–Protein Interactions	6
1.2.1.2	Fc Glycosylation	8
1.2.1.3	Hinge and Interchain Disulfide Bonds	8
1.3	The Neonatal Fc Receptor	9
1.3.1	FcRn Function and Expression	9
1.3.2	Species Difference in FcRn	13
1.3.3	Engineering to Modulate Pharmacokinetics	14
1.3.3.1	Fc Engineering	14
1.3.3.2	Other Engineering Efforts to Modify PK of an IgG or Fc Fusion	15
1.4	Introduction to FcγR- and Complement-Mediated Effector Functions	16
1.4.1	Cell Lysis and Phagocytosis Mediation	17
1.4.2	FcγR-Mediated Effector Functions	17
1.4.2.1	FcγR Biology	17
1.4.2.2	Expression Profiles	18
1.4.2.3	Therapeutic Relevancy	19
1.4.3	Complement	20
1.4.3.1	C1q Biology	20
1.4.3.2	Therapeutic Relevancy	20
1.4.4	Modifying Effector Functions	21
1.4.4.1	FcγR-Dependent Effector Function	21
1.4.4.2	Engineering	22
1.4.4.3	Glycoengineering	22

1.4.4.4	Reducing and Silencing Effector Function	23
1.5	Current Trends in Antibody Engineering	25
1.5.1	Bispecific	25
1.5.2	Drug Conjugates	26
	References	28

Part One Methods of Production for Fc-Fusion Proteins 45

2 Fc-Fusion Protein Expression Technology 47

Jody D. Berry, Catherine Yang, Janean Fisher, Ella Mendoza, Shanique Young, and Dwayne Stupack

2.1	Introduction	47
2.2	Expression Systems Used for Fc-Fusion Proteins	50
2.2.1	Expression Using Mammalian Cell Lines	50
2.2.1.1	Host Cells	51
2.2.1.2	Codon Optimization	52
2.2.1.3	Vectors	52
2.2.1.4	Stable versus Transient Expression	53
2.2.1.5	Viral Transduction and Transfection Methods	55
2.2.2	Expression Using Prokaryotic Cells	57
2.2.2.1	Vectors	59
2.2.3	Expression Using Baculovirus/Insect Cells	60
2.2.3.1	Host Cells	61
2.2.3.2	Vectors	61
2.2.3.3	Additional Considerations	62
2.3	Summary	62
	References	62

3 Cell Culture-Based Production 67

Yao-Ming Huang, Rashmi Kshirsagar, and Barbara Woppmann, and Thomas Ryll

3.1	Introduction	67
3.2	Basic Aspects of Industrial Cell Culture	69
3.2.1	The Central Role of the Production Cell Line	69
3.2.2	Production Systems	70
3.2.3	Production Mode: Fed-Batch or Perfusion?	71
3.2.4	Scale-Up	73
3.2.5	Raw Materials and Process Control	74
3.2.6	How to Develop or Optimize a Culture Production Process for Fc-Fusion Molecules	74
3.3	Specific Process Considerations for Fc-Fusion Molecules	77
3.3.1	Product Quality Challenges	77
3.3.2	Process Strategies and Process Parameters	78
3.3.2.1	Temperature and Misfolding	78

3.3.2.2	Other Process Parameters	79
3.3.2.3	Glycosylation	81
3.4	Case Studies	82
3.4.1	LTBr-Fc (Baminercept)	82
3.4.2	rFVIII-Fc	85
3.5	Conclusions	87
	References	87
4	Downstream Processing of Fc-Fusion Proteins	97
	<i>Abhinav A. Shukla and Uwe Gottschalk</i>	
4.1	Introduction and Overview of Fc-Fusion Proteins	97
4.2	Biochemistry of Fc-Fusion Proteins	99
4.3	Purification of Fc-Fusion Proteins from Mammalian Cells	100
4.3.1	Platform Approaches for Downstream Purification	100
4.3.2	Comparison of Protein A Chromatography, Viral Inactivation, and Polishing Steps	103
4.4	Purification of Fc-Fusion Protein from Microbial Systems	107
4.5	Future Innovations in Fc-Fusion Protein Downstream Processing	109
4.6	Conclusions	110
	References	111
5	Formulation, Drug Product, and Delivery: Considerations for Fc-Fusion Proteins	115
	<i>Wenjin Cao, Deirdre Murphy Piedmonte, and Margaret Speed Ricci, and Ping Y. Yeh</i>	
5.1	Challenges of Molecule Design and Protein Formulation	115
5.2	The Promise of Fc-Fusion Proteins	116
5.3	Current Landscape of Commercial Antibody-Related Products	118
5.4	Fc Conjugates Compared to mAb Counterparts	118
5.5	Factors in Selecting Liquid versus Lyophilized Formulations	126
5.6	Advantages and Disadvantages of a Lyophilized Product	126
5.7	The General Lyophilization Formulation Strategy for Fc-Fusion Proteins	127
5.7.1	pH and Buffer	128
5.7.2	Stabilizing Agents (Cryoprotectant and Lyoprotectant)	129
5.8	Bulking Agent	132
5.9	Surfactant	134
5.10	The Impact of Residual Moisture	135
5.11	Practical Considerations for Low-Protein-Concentration Lyophilized Products	138
5.12	Drug Delivery Considerations	139
5.13	Device Considerations	141
5.14	Assessing Feasibility of a Multidose Formulation	142

5.15	Overage Considerations	142
5.16	Summary	143
	References	144

6 **Quality by Design Applied to a Fc-Fusion Protein: A Case Study** 155

Alex Eon-Duval, Ralf Gleixner, Pascal Valax, Miroslav Soos, Benjamin Neunstoecklin, Massimo Morbidelli, and Hervé Broly

6.1	Introduction	155
6.1.1	Atacicept: A Novel Immunomodulator with B Cell Targeting Properties	155
6.1.2	Molecular Characteristics	155
6.1.3	Quality by Design Concept	157
6.2	Critical Quality Attributes	159
6.3	Critical Process Parameters	160
6.4	Process Characterization	161
6.5	Global Multistep Design Space	164
6.6	Robustness Studies	168
6.7	Adaptive Strategy	169
6.8	Engineering Design Space	171
6.8.1	Principle of the Engineering Design Space	171
6.8.2	The Shear Stress as One Element of the Engineering Design Space	173
6.9	Control Strategy	176
6.9.1	Process Controls	177
6.9.2	Testing Controls	177
6.9.3	Process Monitoring	179
6.9.4	Material Control	179
6.10	Continuous Process Verification	180
6.11	Expanded Change Protocol and Continual Improvement	182
6.12	Business Case	183
	References	187

7 **Analytical Methods Used to Characterize Fc-Fusion Proteins** 191

Esohe Idusogie and Michael Mulkerrin

7.1	Background	191
7.2	Product Characterization	193
7.2.1	Physiochemical Analysis	195
7.2.1.1	Measurement of Strength by Absorbance at 280 nm	195
7.2.1.2	Determination of Identity and Evaluation of Charge Variants	195
7.2.1.3	Measurement of Purity and Integrity	198
7.2.1.4	Mass Analysis and Confirmation of Primary Structure	198
7.2.1.5	Oligosaccharide Analysis	199
7.2.1.6	Purity (Product-Related Variants)	200
7.2.2	Measurement of Potency	201
7.2.3	Process-Related Impurities and Contaminants	204

7.2.3.1	Host Cell Protein	204
7.2.3.2	Residual DNA	205
7.2.3.3	Residual Protein A	206
7.2.3.4	Tests for Contaminants	206
7.3	Characterization of the Reference Standard	207
7.4	Typical Product Release and Stability Assays	207
7.5	Analytical Method Qualification and Validation	210
	References	212

Part Two Case Studies of Therapeutic Fc-Fusion Proteins 217

8 Introduction to Therapeutic Fc-Fusion Proteins 219

Jody D. Berry

8.1	Therapeutic Fc-Fusion Proteins	219
8.2	Background	221
8.3	Fc-Fusion Constructs Have Increased In Vivo Stability	222
8.4	Immunoglobulin-Mediated Effector Function	223
8.5	Considerations in Fc-Fusion Protein Design	226
8.6	Fc-Fusion Proteins Approved for Use in the United States	226
8.6.1	Alefacept	226
8.6.2	Etanercept	227
8.6.3	Abatacept and Belatacept	227
8.6.4	Aflibercept	228
8.6.5	rFVIIIIFc and rFIXFc	228
8.6.6	Rilonacept	229
8.6.7	Romiplostim	229
8.6.8	Trebananib	229
8.7	Concluding Remarks	229
	References	230

9 Alefacept 233

Deborah A. Farson

9.1	Introduction	233
9.2	Chronic Plaque Psoriasis	233
9.3	Conventional Treatments for Psoriasis	234
9.4	Preclinical Development	234
9.4.1	CD2/LFA-3	234
9.4.2	Fusion Protein Alefacept (LFA3TIP)	236
9.5	Preclinical Primate Studies	237
9.6	Phase 1 and 2 Human Clinical Studies	240
9.7	Phase 3 Studies	240
9.7.1	Study Design	242
9.7.1.1	Eligibility	242
9.7.1.2	Dosing and Blood Work	244

9.7.1.3	Endpoints	244
9.7.1.4	Statistical Analysis	244
9.7.1.5	Intravenous Studies 711 and 724	244
9.7.1.6	Intramuscular Studies 712 and 717	245
9.7.2	Efficacy	245
9.7.2.1	Patient Population	245
9.7.2.2	CD4 Monitoring	246
9.7.2.3	PASI and PGA Results	246
9.7.2.4	Quality of Life	247
9.7.2.5	Remittance	247
9.7.3	Multiple Courses of Treatment	247
9.8	Clinical Pharmacology	248
9.9	Clinical Safety	249
9.9.1	Adverse Events	249
9.9.2	Infection	250
9.9.3	Cancer	250
9.9.4	Laboratory Tests	250
9.10	Amevive Discontinued	250
	References	251

10 Etanercept 255

Johanna Grossman and Steven M. Chamow

10.1	Introduction	255
10.1.1	TNF Structure and Function	255
10.1.2	TNF Receptor Types	256
10.1.3	TNF Receptor Signaling	256
10.1.4	Role of TNF in Chronic Inflammatory Disease	259
10.1.5	Rheumatoid Arthritis	259
10.1.6	Juvenile Idiopathic Arthritis	260
10.1.7	Psoriatic Arthritis	260
10.1.8	Ankylosing Spondylitis	260
10.1.9	Crohn's Disease	261
10.1.10	Ulcerative Colitis	261
10.1.11	Psoriasis	261
10.2	Design, Construction, and Characterization of TNFR-Fc-Fusion Protein	262
10.2.1	State of Therapeutic Antibodies and Rationale for a Receptor-Fc-Fusion Protein	262
10.3	Etanercept Preclinical Development	264
10.3.1	Binding and TNF Inhibitory Activity	265
10.3.2	Inhibition of TNF Activity	265
10.3.3	Preclinical Efficacy	266
10.3.4	Pharmacokinetics and Pharmacodynamics	266
10.3.5	Toxicology	267
10.4	Etanercept Key Clinical Trials	267

10.4.1	Rheumatoid Arthritis	267
10.4.2	Polyarticular Juvenile Idiopathic Arthritis	269
10.4.3	Psoriatic Arthritis	270
10.4.4	Ankylosing Spondylitis	270
10.4.5	Plaque Psoriasis	271
10.4.6	Other Potential Indications	272
10.5	Competitive Landscape	273
10.6	Conclusions	273
	References	274
11	Abatacept and Belatacept	283
	<i>Robert J. Peach</i>	
11.1	Introduction	283
11.2	Design, Construction, and Characterization of Abatacept	285
11.3	Immunosuppressive Properties of Abatacept	288
11.4	Rational Design and Characterization of Belatacept	291
11.5	Belatacept Activity in Primate Renal Transplant Studies	294
11.6	Abatacept Clinical Development	295
11.7	Belatacept Clinical Development	299
11.8	Concluding Remarks	302
	References	303
12	Aflibercept	311
	<i>Angela L. Linderholm and Steven M. Chamow</i>	
12.1	Introduction	311
12.2	Clinical Indications	311
12.2.1	Age-Related Macular Degeneration	311
12.2.2	Macular Edema with CRVO	315
12.2.3	Metastatic Colorectal Cancer	316
12.3	Characterization of Aflibercept	317
12.4	Preclinical Studies with Aflibercept	320
12.5	Clinical Studies with Aflibercept	325
12.5.1	Aflibercept and AMD	325
12.5.2	Aflibercept and Cancer	327
12.5.2.1	Single-Agent Phase 1 Studies	327
12.5.2.2	Combination Phase 1 Studies	332
12.5.2.3	Single-Agent Phase 2 Studies	332
12.5.2.4	Combination Phase 2 and 3 Studies	335
12.6	Summary	336
	References	336
13	Recombinant Factor VIII– and Factor IX–Fc Fusions	351
	<i>Robert T. Peters and Judy R. Berlfein</i>	
13.1	Introduction	351
13.1.1	Treatment for Hemophilia	351

13.2	Structure and Function of Factor IX and Factor VIII	352
13.2.1	Factor IX	352
13.2.2	Factor VIII	354
13.3	Rationale and Design of rFIXFc- and rFVIIIIFc-Fusion Proteins	356
13.3.1	Fc/FcRn Pathway for Half-Life Extension and the Monomeric Fc-Fusion	356
13.3.2	Beyond Science: Outside Factors for Applying Monomeric Fc Technology to Hemophilia	356
13.3.3	rFIXFc: Putting It Into Practice	358
13.3.4	rFVIIIIFc: Putting It Into Practice	363
13.4	Development of a Clinical Candidate and Beyond	365
13.4.1	Preclinical and Clinical Development	365
13.4.1.1	Preclinical Development	366
13.4.1.2	Clinical Development	367
	References	368

Index	371
--------------	------------